NASDAQ · Biotechnology

KPTI (KPTI) Stock

$1.85 -10.19% NASDAQ: KPTI Healthcare

Valuation

MetricValue
Price$1.85
Market Cap$41.93M
P/E Ratio-0.09
P/B Ratio-0.17
P/S Ratio0.30
EPS (TTM)$-17.93
52-Week High$10.99
52-Week Low$1.79
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE77.63%
ROA-201.89%
ROCE359.36%
Gross Margin-62.33%
Operating Margin-62.33%
Net Margin-153.28%
Debt/Equity-0.65
Current Ratio1.12

Annual Financials (USD)

Metric20212022202320242025
Revenue$210.0M$157.0M$146.0M$145.0M$146.0M
Operating Profit$-98.0M$-142.0M$-130.0M$-119.0M$-91.0M
Net Profit$-124.0M$-165.0M$-143.0M$-76.0M$-196.0M
EPS$-24.75$-30.28$-18.79$-9.41$-17.93
Op Margin-46.8%-90.5%-88.7%-82.2%-62.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$305.0M$358.0M$240.0M$164.0M$108.0M
Total Liabilities$385.0M$375.0M$377.0M$350.0M$401.0M
Cash$190.0M$135.0M$52.0M$62.0M$61.0M
Borrowings$181.0M$179.0M$177.0M$195.0M$234.0M

Latest News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire · Jul 1, 2026 Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update Simply Wall St. · Jun 25, 2026 Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress PR Newswire · Jun 14, 2026 Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress GlobeNewswire · Jun 14, 2026 How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI) Simply Wall St. · Jun 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-107.0M$-150.0M$-93.0M$-127.0M$-75.0M
Investing Cash Flow$136.0M$-104.0M$8.0M$95.0M$43.0M
Financing Cash Flow$4.0M$4.0M$0$-43.0M$0
Net Cash Flow$108.0M$-61.0M$-84.0M$10.0M$-2.0M
Free Cash Flow$-113.0M$-150.0M$-93.0M$-128.0M$-75.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.17
FCF Yield-147.11%
Quick Ratio0.76
Interest Coverage-1.67
Return 1Y109.85%
Return 3Y-57.22%
Return 5Y-92.74%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGS $6.09 +3.92% -2.29 $37.69M 0.00%
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
CVM $1.61 -0.62% -0.23 $11.06M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
INMB $2.24 -2.61% -2.44 $59.55M 0.00%

About KPTI

KPTI is led by CEO Richard A. Paulson, employs 279 people, headquartered in US, publicly traded since 2013.

KPTI stock trades at $1.85 with a market capitalization of $41.93M. The stock is valued at a price-to-earnings (P/E) ratio of -0.09, price-to-book of -0.17, price-to-sales of 0.30. Over the past 52 weeks the stock has ranged between $1.79 and $10.99, and currently trades 83.2% below its 52-week high.

On profitability, KPTI generates a return on equity (ROE) of 77.63% — well above the market average, a sign of a high-quality business, return on capital employed of 359.36%, an operating margin of -62.33%, a net profit margin of -153.28%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides